688098
vs
S
Shanghai Composite
688098
Over the past 12 months, Shanghai Shen Lian Biomedical Corp has significantly outperformed Shanghai Composite, delivering a return of +68% compared to the Shanghai Composite's +23% growth.
Stocks Performance
688098 vs Shanghai Composite
Performance Gap
688098 vs Shanghai Composite
Performance By Year
688098 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Shanghai Shen Lian Biomedical Corp
Glance View
Shanghai Shen Lian Biomedical Corp. engages in the research, development, and manufacture of vaccines for the animal farming industry. The company is headquartered in Shanghai, Shanghai and currently employs 297 full-time employees. The company went IPO on 2019-10-28. The firm is committed to the research & development of foot and mouth disease vaccines, which are used to protect animals from foot and mouth diseases. The firm's main product are swine foot and mouth disease vaccines, and it also provides cattle foot and mouth disease vaccines, other swine vaccines, and other veterinary diagnostic reagents. The firm mainly sells its products within domestic market.
